Anaplastic lymphoma kinase (ALK), which is expressed highly in the mammalian nervous system, is a therapeutic target for the treatment of NSCLC.6 Moreover, the echinoderm microtubule‐associated protein‐like 4 (EML4)‐ALK fusion protein is a type of ALK fusion protein that plays an important role in tumorigenesis in approximately 5% of NSCLC cases.7 The first FDA‐approved ALK inhibitor (ALKi) for the treatment of NSCLC with ALK fusion proteins (ALK‐positive, ALK+) is an aminopyridine compound, crizotinib. Here, EML4 is linked to non-small cell lung carcinoma.